Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 526 to 550 of 2013

TitleReference numberPublishedLast updated
Neuropad for detecting preclinical diabetic peripheral neuropathyHTG486
Prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasiaHTG639
Removal, preservation and subsequent reimplantation of ovarian tissue to prevent symptoms from the menopauseHTG640
Colorectal cancer prevention: colonoscopic surveillance in adults with ulcerative colitis, Crohn's disease or adenomasCG118
Melphalan for haematological diseases before allogeneic haematopoietic stem cell transplant (terminated appraisal)TA822
Dexamethasone intravitreal implant for treating diabetic macular oedemaTA824
Self-harm: assessment, management and preventing recurrenceNG225
Brolucizumab for treating diabetic macular oedemaTA820
Faecal microbiota transplant for recurrent Clostridioides difficile infectionHTG638
iFuse for treating chronic sacroiliac joint painHTG488
Avalglucosidase alfa for treating Pompe diseaseTA821
Transcutaneous electrical neuromuscular stimulation for urinary incontinenceHTG636
Superficial venous arterialisation for chronic limb threatening ischaemiaHTG637
Focal resurfacing implants to treat articular cartilage damage in the kneeHTG635
Type 1 diabetes in adults: diagnosis and managementNG17
Nivolumab with ipilimumab for untreated unresectable malignant pleural mesotheliomaTA818
Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapiesTA819
Ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infectionsAMR1
Cefiderocol for treating severe drug-resistant gram-negative bacterial infectionsAMR2
Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancerTA816
Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrenceTA817
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDsTA815
SecurAcath for securing percutaneous cathetersHTG440
Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancerTA812
Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitorsTA813

Results per page

  1. 10
  2. 25
  3. 50
  4. All